CD14 positive cells accelerate hematopoietic stem cell engraftment.

Area of Science:

• Hematology
• Immunology
• Cell Biology

Background:

• Hematopoietic stem and progenitor cell (HSPC) engraftment is crucial for successful transplantation.
• Limited cell doses, common in cord blood (CB) transplantation and HSC gene therapy, pose a significant challenge to engraftment.
• Identifying strategies to improve HSPC engraftment is a high-priority research goal.

Purpose of the Study:

• To investigate the potential of monocytes to improve HSPC engraftment.
• To explore the mechanisms underlying HSC-monocyte interactions.
• To assess the efficacy of monocytes in enhancing engraftment of limited cell doses.

Main Methods:

• Utilized a xenogeneic model of HSC transplantation.
• Co-cultured human CD34+ cells with monocytes, including the CD14+CD16- classical subset.
• Analyzed cell survival, stemness, and engraftment efficiency.
• Investigated the roles of soluble factors and cell-contact dependent pathways (JAG/NOTCH, COX-2/PGE2).

Main Results:

• Monocytes significantly improved the engraftment of both CB-derived and lentivirus-transfected CD34+ cells.
• Monocyte co-culture increased the survival and stemness of CB-CD34+ cells.
• HSC-monocyte crosstalk involves both soluble factors and direct cell contact via JAG/NOTCH and COX-2/PGE2 pathways.

Conclusions:

• Monocytes, especially the CD14+CD16- subset, are effective in enhancing HSPC engraftment.
• Monocyte infusion can overcome limitations associated with low cell doses in transplantation.
• Targeting HSC-monocyte crosstalk presents a promising therapeutic strategy for improving transplantation outcomes.